Trials / Completed
CompletedNCT04818320
Favipiravir in High-risk COVID-19 Patients
Efficacy of Favipiravir in High Risk COVID-19 Patients: A Randomised, Open-label, Multicenter Clinical Trial
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 500 (actual)
- Sponsor
- Penang Hospital, Malaysia · Other Government
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The study aims to investigate the efficacy of favipiravir in high-risk COVID-19 patients. The study population includes symptomatic mild-to-moderate COVID-19 inpatients, within first 7 days of illness, who are 50 years old and above, and have 1 or more comorbidities. The study is designed as a randomised, open-label, multicenter clinical trial where the patients are randomised 1:1 to groups receiving favipiravir (5 days) versus no favipiravir.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Favipiravir | Day 1: 1800mg BD, day 2-5: 800mg BD |
Timeline
- Start date
- 2021-02-16
- Primary completion
- 2021-07-01
- Completion
- 2021-07-13
- First posted
- 2021-03-26
- Last updated
- 2021-11-24
Locations
1 site across 1 country: Malaysia
Source: ClinicalTrials.gov record NCT04818320. Inclusion in this directory is not an endorsement.